<?xml version="1.0" encoding="UTF-8"?>
<p>Sinovac Biotech (China) in collaboration with several Universities, Public Health institutions and the Medical Academy of the Army of China have been able to produce a whole virus inactivated vaccine adjuvanted by alum that was stable and showed 99.8 to 100% sequence identity to 10 other isolates also obtained from broncheoalveolar fluid (BALF) of hospitalized patients (five in intensive care), from China, Italy, United Kingdom, Switzerland and Spain (
 <xref rid="B40" ref-type="bibr">40</xref>). The virus was propagated in cultures of Vero cells 
 <italic>in vitro</italic> and inactivated with Î²
 <italic>-</italic>propiolactone (
 <xref rid="B40" ref-type="bibr">40</xref>). The use of Alum adjuvant is approved for human vaccines because it induces strong antibody responses, mainly of the IgG1 and IgE types that show efficacy against virus or bacterial diseases, which need neutralizing antibodies to be controlled. However, alum is a poor promoter of the cellular immune responses against pathogens (
 <xref rid="B41" ref-type="bibr">41</xref>).
</p>
